Private treatment costs and waiting times in New Zealand

QuoteHub Research — August 2026 edition

This report joins two public datasets that are rarely read together: Health New Zealand’s own waitlist data, which counts every person queued for a specialist assessment or treatment in the public system, and QuoteHub’s register of verified NZ private treatment cost observations, which records what named providers and insurers publish about the cost of skipping that queue. Every waiting-time figure below is computed from Health NZ’s published extract; every cost figure is a dated observation from a named source; and where no figure exists, the gap is stated rather than estimated.

Published 18 August 2026 · waiting-time sources retrieved 18 August 2026 · cost register verified 15 August 2026 · download the dataset (CSV)

Executive summary

At 31 March 2026, 273,621 people were on New Zealand’s two public hospital queues — 196,166 waiting for a first specialist assessment and 77,455 waiting for treatment — and 103,152 of them, more than one in three, had already waited longer than the four-month target. Three findings stand out from the data.

1. The queue before the queue is two and a half times bigger than the queue itself. Public debate tracks the treatment waitlist (77,455 people), but 196,166 people were waiting just to see a specialist for the first time — and the four-month breach rate was worse at that first stage (38.7% versus 35.0%). A patient’s real wait is the two queues added together, and only the second one is widely reported.
2. Orthopaedics is the system’s deepest bottleneck at both stages — and the most expensive to bypass. 56.5% of the 36,937 people waiting for an orthopaedic first assessment had waited over four months, the worst share of any major specialty, and 44.5% of the 14,733 on the orthopaedic treatment list had too. The private alternative for the flagship orthopaedic procedures — hip and knee replacement — carries observed costs in the tens of thousands of dollars per operation in published insurer claims data. The wait is longest exactly where the private exit costs most.
3. For half of common procedures, no private price is published anywhere in New Zealand. Of the 86 procedures in QuoteHub’s evidence register, 43 — exactly half — have no published NZ price from any provider or insurer. Only 24 have a provider-published price, and a further 19 are visible only through insurer claims-cost data. A consumer weighing a four-month-plus public wait against going private mostly cannot find out what private treatment would cost.

The honest counterweight: the past year shows measurable improvement. Health NZ’s official target measure for elective treatment improved 7.6 percentage points year on year to 64.9% in the March 2026 quarter, the treatment waitlist has fallen 8% from its late-2024 peak, and more assessments and treatments were delivered in the March 2026 quarter than in the same quarter a year earlier. The system is recovering from its 2023–2025 peak — but it remains far worse than a decade ago, when the over-four-month share was in low single digits on both queues.

How long New Zealanders are waiting for public treatment

Two separate waits sit between a New Zealander and publicly funded surgery: the wait to see a specialist for the first time (the FSA queue), and — for those accepted for treatment — the wait for the operation itself. At 31 March 2026, computed from Health New Zealand’s waitlist detailed data extract (Q3 2025/26, retrieved 18 August 2026), 196,166 people were on the FSA queue with 76,007 (38.7%) waiting over four months, and 77,455 people were on the treatment queue with 27,145 (35.0%) waiting over four months.

The decade view is stark. In March 2015, 0.3% of the FSA queue and 1.1% of the treatment queue had waited over four months. Both shares peaked in the 2023–2025 period — 43.9% of the treatment queue in March 2023 and 42.3% of the FSA queue in March 2025 — and both have improved since. The government’s official target, recorded in the DPMC Target 2 factsheet (quarter ending March 2026), is that 95% of people wait less than four months for elective treatment by 2030, against a September 2023 baseline of 62.0%.

The two public queues at 31 March each year, 2015–2026: people waiting for a first specialist assessment (FSA) and people waiting for treatment, with the share of each who had waited over four months.

Source: computed by QuoteHub from Health New Zealand’s

(Q3 2025/26 edition, data to 31 March 2026), retrieved

. Cells of 1–4 are suppressed by Health NZ and excluded from these sums.

The official quarterly scoreboard

Health New Zealand’s own published result for the March 2026 quarter, in its Q3 2025/26 health target factsheets (retrieved 18 August 2026), was 64.9% of the treatment waitlist waiting less than four months — up 7.6 percentage points on the same quarter a year earlier (57.3%), against a 2025/26 milestone of 70%. For first specialist assessments the result was 61.2%, up 3.0 points on a year earlier, against a milestone of 65%. The same factsheets record 51,089 people treated from the waitlist in the quarter (up 5.5% year on year) and 178,349 first specialist assessments delivered (up 7%), with the treatment waitlist down 8% from its quarter-two 2024/25 peak — improvement Health NZ attributes partly to outsourced private-sector capacity, including the Elective Boost programme’s additional 21,000 hip, knee, cataract and other procedures through June 2026.

Where the waits are longest

Waiting is not evenly distributed: the share of the treatment queue waiting over four months at 31 March 2026 ranged from 10.9% in Wairarapa to 49.1% in Northland — a 4.5-fold gap between districts — and orthopaedic surgery carried both the largest treatment waitlist and one of the worst breach rates of any specialty. The South Island (Te Waipounamu) region had the worst share on both queues: 45.8% of its FSA waitlist and 40.1% of its treatment waitlist had waited over four months, against 35.5% and 28.4% respectively in the Central region.

By specialty

Treatment waitlist by specialty, 31 March 2026 (ten largest).

Source: computed by QuoteHub from Health New Zealand’s

(Q3 2025/26 edition, data to 31 March 2026), retrieved

. Cells of 1–4 are suppressed by Health NZ and excluded from these sums.

First-specialist-assessment waitlist by specialty, 31 March 2026 (eight largest).

Source: computed by QuoteHub from Health New Zealand’s

(Q3 2025/26 edition, data to 31 March 2026), retrieved

. Cells of 1–4 are suppressed by Health NZ and excluded from these sums.

By district

Treatment waitlist by district at 31 March 2026, sorted by the share waiting over four months, worst first. Small districts have small lists — West Coast and Wairarapa each had under 500 people waiting.

Source: computed by QuoteHub from Health New Zealand’s

(Q3 2025/26 edition, data to 31 March 2026), retrieved

. Cells of 1–4 are suppressed by Health NZ and excluded from these sums.

What private treatment costs — and where no price exists

New Zealand has no official register of private treatment prices, so the cost side of this report is built the only honest way possible: from dated observations of what named providers publish on their own pricing pages and what named insurers publish from their claims data. QuoteHub’s procedure register applies that named-provider-anchor method to 86 common procedures, and its most important result is how little evidence exists at all.

QuoteHub’s procedure register currently covers 86 procedures across 11 clinical categories. For 24 of them, a named NZ clinic, surgeon or radiology group publishes a price on its own pricing page. For another 19, the only public figure is an insurer’s published claims-cost range — real amounts a named insurer reports paying across many claims, labelled as claims-derived wherever it appears. For the remaining 43 — 50% of the register — no NZ provider or insurer publishes any price at all. In total the register holds 61 dated, provider-named cost observations, each linked to its source in the Treatment Cost Explorer and in the CSV download below.

That evidence void is itself a finding. A patient told they face a long public wait cannot, for half of common procedures, find out from any published NZ source what going private would cost. Where figures do exist they are indicative observations, not quotes — an actual private price depends on the surgeon’s and anaesthetist’s fees, the hospital, the prosthesis or technology used, and the complexity of the case.

Queue pressure and private cost, side by side

The table below joins the two datasets: for each high-pressure specialty on the public treatment queue, it shows an example procedure and every published NZ cost observation for it — or the absence of one. The urology and cardiology rows show the evidence void directly: more than 25,000 people were queued across those two specialties’ assessment and treatment lists at 31 March 2026, and no NZ source publishes a private price for two of their defining procedures.

Public treatment-queue pressure by specialty at 31 March 2026, joined with observed NZ private costs for example procedures in that specialty. Waiting figures:

Source: computed by QuoteHub from Health New Zealand’s

(Q3 2025/26 edition, data to 31 March 2026), retrieved

. Cells of 1–4 are suppressed by Health NZ and excluded from these sums.

Cost figures: dated observations from the named provider or insurer data sheet, linked in each cell — indicative observations, not quotes; where no NZ source publishes a price, the cell says so.

What this means for consumers

The practical meaning of this data is a decision most people never think about until a referral letter arrives: if a public wait stretches past four months, the alternatives are to wait, to self-fund private treatment at the observed costs above, or to hold health insurance that pays those costs. None of these is automatically right. Public treatment is free and clinically prioritised — urgent cases move fast, and Health NZ’s own data shows the queues shortening over the past year. Self-funding buys certainty for those who can absorb a five-figure bill. Insurance spreads that cost, but only works if the cover was in place before the condition arose.

Two honest caveats belong next to any insurance framing. First, mainstream NZ health policies exclude pre-existing conditions unless disclosed and accepted — cover bought after symptoms appear will generally not fund that condition’s treatment, and whether any specific procedure is covered depends on the policy’s terms, its exclusions and the insurer’s underwriting. Nothing in this report predicts what any insurer would accept or pay. Second, not everything in the tables above is insurable: fertility treatment and most cosmetic procedures are excluded across the market, and injury-caused treatment is usually ACC territory. The register records an insurance-relevance flag for each of the 86 procedures — it is general orientation, not advice.

If these numbers are part of a decision you are weighing, the

health insurance overview

Methodology

This report uses public-source data only: no QuoteHub customer, enquiry or CRM data appears anywhere in it, so no small-cell privacy issues arise from our side, and the only suppression in the data is Health New Zealand’s own. This is the permanent URL for the report — future editions update this page in place, with each change recorded in the changelog below, so citations keep resolving.

Waiting-time data

• Primary source: Health New Zealand’s Waitlist detailed data extracts workbook, Q3 2025/26 (published on the health targets performance resources page), covering July 2015 to March 2026 at region, district and specialty level. Retrieved 18 August 2026.
• Computation: for each snapshot we sum the extract’s “Total Waiting” and “Waiting under 120 days” columns and report the share waiting 120 days or more — the four-month measure Health NZ’s own target uses. All figures are point-in-time waitlist snapshots at month end, not counts of people treated.
• Suppression: Health NZ suppresses cells of 1–4 as “<5”; we exclude suppressed cells from sums. At 31 March 2026 this affects at most 169 cells nationally on the treatment queue — assigning them their extreme possible values moves the national over-four-months share by at most half a percentage point (34.3%–35.3% around our reported 35.0%), and less on the FSA queue (about a dozen suppressed cells).
• Cross-validation: our computed under-four-months shares match the officially published figures within revision tolerance — 65.0% computed versus 64.9% published by Health NZ for the treatment queue at March 2026, 61.3% versus 61.2% for the FSA queue, and 64.8% versus the 64.5% in the DPMC Target 2 factsheet at December 2025. The extract is drawn from live administrative data and Health NZ notes it may differ slightly from previously published static figures.
• A definitional note for anyone reusing these figures: the waitlist share (“35.0% of those waiting have waited over four months”) and the DPMC target headline are snapshot measures of the queue, not of everyone treated in a period. Adding the FSA and treatment queues counts people at different stages of one pathway; a person can appear in each queue at different times, and the two waits are sequential for those who progress to treatment.
• Re-verification: waiting-time figures are updated when Health NZ publishes each quarterly release; the next edition will incorporate the Q4 2025/26 (April–June 2026) data when published.

Cost observations

• No official source of NZ private treatment prices exists, so every cost figure uses the named-provider-anchor method: transcribed from a named provider’s published pricing or a named insurer’s published claims-cost data — never derived, never averaged from memory, and never taken from QuoteHub’s own earlier indicative figures. Each observation records who published it, the date it was last seen stating that figure, and a link to the source.
• Where no NZ provider or insurer publishes a figure for a procedure, the register states the gap rather than filling it — 43 of the 86 procedures are in that state, and that count is reported as a finding, not hidden.
• Insurer claims-data ranges are what a named insurer reports actually paying across many claims in a stated period — real money for real treatment, but not an advertised price; they are labelled claims-derived wherever they appear.
• The register was verified on 15 August 2026; every observation sits on a 180-day re-observation cycle with the next scheduled re-verification due by 11 February 2027. Providers change prices between checks — confirm any current figure with the provider directly.
• Limitations: observations are indicative, not quotes; several are claims-derived ranges whose underlying periods differ; coverage is weighted toward procedures NZ consumers actually search for; and no premium (insurance price) figures appear anywhere in this report or its dataset.

Download the dataset

The full cost-observation dataset behind this report is a single CSV — one row per sourced observation (61 rows across 43 procedures), public-source data only: qh-treatment-costs-2026.csv. The waiting-time source workbook is published by Health New Zealand at the links in the methodology above.

Field definitions for qh-treatment-costs-2026.csv.

Citing this report

This report may be cited freely with attribution. Suggested citation:

QuoteHub Treatment Costs & Waiting Times Report, August 2026. QuoteHub, www.quotehub.co.nz/research/treatment-costs-waiting-times.

Media enquiries are welcome via the QuoteHub contact page; a licensed financial adviser is available for comment on the insurance aspects of the data.

Changelog and corrections

• 18 August 2026 — first edition published (waiting-time data to 31 March 2026; cost register of 15 August 2026).

Material corrections are noted on this page rather than made silently, per

QuoteHub’s editorial and corrections policy

About this report

This report is general information, not personalised financial advice, and no cost figure in it is a quote. Financial advice is provided by Craig Smith Business Services Limited, trading as Smiths Insurance & KiwiSaver, a licensed Financial Advice Provider (FSP712931). Waiting-time sources retrieved 18 August 2026; cost register last verified 15 August 2026.

Discuss what these findings mean for you with a licensed adviser · free, no obligation.

Explore related pages: Life Insurance, Income Protection, Health Insurance, Trauma Insurance, Free Will.